GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO)

INR 2306.25

(-1.23%)

Net Debt Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual net debt in 2023 was -674.11 Million INR , down -247.45% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly net debt in 2024 Q2 was -386.5 Million INR , down 0.0% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported annual net debt of -194.01 Million INR in 2022, up 92.71% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported annual net debt of -2.66 Billion INR in 2021, up 28.19% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported quarterly net debt of -386.5 Million INR for 2024 Q2, down 0.0% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported quarterly net debt of -674.11 Million INR for 2023 Q4, down -104.2% from previous quarter.

Annual Net Debt Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual Net Debt of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	Net Debt	Net Debt Growth
2023	-674.11 Million INR	-247.45%
2022	-194.01 Million INR	92.71%
2021	-2.66 Billion INR	28.19%
2020	-3.7 Billion INR	-488.46%
2019	-629.71 Million INR	35.87%
2018	-981.93 Million INR	50.93%
2017	-2 Billion INR	77.11%
2016	-8.74 Billion INR	-676.84%
2015	-1.12 Billion INR	-0.29%
2014	-1.12 Billion INR	94.44%
2013	-20.17 Billion INR	1.3%
2012	-20.44 Billion INR	-2.47%
2011	-19.95 Billion INR	0.13%
2010	-19.97 Billion INR	-15.58%
2009	-17.28 Billion INR	-81.74%
2008	-9.51 Billion INR	-513.72%
2007	-1.54 Billion INR	-412.45%
2006	-302.4 Million INR	29.15%
2005	-426.82 Million INR	36.88%
2004	-676.24 Million INR	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	- INR	100.0%
2024 Q2	-386.5 Million INR	0.0%
2023 Q4	-674.11 Million INR	-104.2%
2023 Q1	16.54 Billion INR	8625.64%
2023 Q2	-525 Million INR	-103.17%
2023 FY	-674.11 Million INR	-247.45%
2023 Q3	16.05 Billion INR	3157.71%
2022 Q4	-194.01 Million INR	-101.49%
2022 FY	-194.01 Million INR	92.71%
2022 Q1	28.3 Billion INR	1163.8%
2022 Q2	-324.5 Million INR	-101.15%
2022 Q3	13.05 Billion INR	4122.28%
2021 Q1	11.37 Billion INR	406.89%
2021 FY	-2.66 Billion INR	28.19%
2021 Q2	-5.68 Billion INR	-150.01%
2021 Q4	-2.66 Billion INR	-122.38%
2021 Q3	11.89 Billion INR	309.09%
2020 Q3	6.96 Billion INR	782.48%
2020 FY	-3.7 Billion INR	-488.46%
2020 Q4	-3.7 Billion INR	-153.17%
2020 Q2	-1.02 Billion INR	-109.62%
2020 Q1	10.61 Billion INR	1786.2%
2019 Q4	-629.71 Million INR	-106.5%
2019 FY	-629.71 Million INR	35.87%
2019 Q1	11.47 Billion INR	1268.91%
2019 Q2	-757.8 Million INR	-106.6%
2019 Q3	9.68 Billion INR	1378.65%
2018 Q4	-981.93 Million INR	0.0%
2018 Q1	12.7 Billion INR	0.0%
2018 FY	-981.93 Million INR	50.93%
2017 FY	-2 Billion INR	77.11%
2016 FY	-8.74 Billion INR	-676.84%
2015 FY	-1.12 Billion INR	-0.29%
2014 FY	-1.12 Billion INR	94.44%
2013 FY	-20.17 Billion INR	1.3%
2012 FY	-20.44 Billion INR	-2.47%
2011 FY	-19.95 Billion INR	0.13%
2010 FY	-19.97 Billion INR	-15.58%
2009 FY	-17.28 Billion INR	-81.74%
2008 FY	-9.51 Billion INR	-513.72%
2007 FY	-1.54 Billion INR	-412.45%
2006 FY	-302.4 Million INR	29.15%
2005 FY	-426.82 Million INR	36.88%
2004 FY	-676.24 Million INR	0.0%

Peer Net Debt Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	Net Debt	Net Debt Difference
Abbott India Limited	-20.51 Billion INR	96.714%
Cipla Limited	-3.15 Billion INR	78.638%
Gland Pharma Limited	-14.67 Billion INR	95.406%
Kopran Limited	850.3 Million INR	179.279%
Marksans Pharma Limited	-4.29 Billion INR	84.305%
NGL Fine-Chem Limited	307.22 Million INR	319.42%
Pfizer Limited	-19.52 Billion INR	96.547%
Sanofi India Limited	-3.87 Billion INR	82.604%
SMS Pharmaceuticals Limited	2.44 Billion INR	127.563%